Recombinant Factor VII Activated and Prothrombin Complex Concentrate Use at a Tertiary Academic Medical Center-Reference-Cited by-同舟云学术

Recombinant Factor VII Activated and Prothrombin Complex Concentrate Use at a Tertiary Academic Medical Center

Published:2014-07-02 Issue:3 Volume:2 Page:151-155
ISSN:2167-4884
Container-title:Current Emergency and Hospital Medicine Reports
language:en
Short-container-title:Curr Emerg Hosp Med Rep

Author:

Reardon David P.,Szumita Paul M.,Connors Jean M.,Atay Julie K.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40138-014-0046-6.pdf

Reference22 articles.

1. Bruce D, Nokes TJC. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:R105.

2. Lynn M, Jeroukhimov I, Klein Y, et al. Updates in the management of severe coagulopathy in trauma patients. Int Care Med. 2002;28:S241–7.

3. •• Vang ML, Hvas AM, Ravn HB. Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol Scand. 2011;55:507–16. This article provides the rationale and evidence supporting the use of prothrombin complex concentrates, fresh frozen plasma, and recombinant Factor VII activated in the reversal of vitamin K antagonists. Reversal of vitamin K antagonists was the most common reason for factor administration at our institution.

4. Ho AMH, Dion PW, Cheng CAY, et al. A mathematical model for fresh frozen plasma transfusion strategies during major trauma resuscitation with ongoing hemorrhage. Can J Surg. 2005;48(6):470–8.

5. • Voils S. Pharmacologic interventions for the management of critical bleeding. Pharmacotherapy. 2007;27(9:2):69S–84S. This article summarizes pharmacological interventions for the management of acute bleeding due to many different coagulopathies. It provides evidence and dosing strategies for available agents.